Blog

A 29-year-old female is presenting to you with complaints of symptoms consistent with RLS that started a couple weeks ago. She tells you that she was recently diagnosed with depression and anxiety a month ago and was started on lorazepam and venlafaxine at that time. She donates blood regularly and takes an iron supplement. Recent labs indicate that CBC and iron studies are normal. Which of the following best explains her new symptoms?

Which of the following best describes the mechanism of action of naloxone?

A 38-year-old woman presents in January with a depressed mood. She has also had a lack of interest in activities, hypersomnia, increased appetite, inappropriate guilt, poor concentration, and thoughts of death. She describes symptoms consistent with having one major depressive episode between the months of January and March in each of the past three years, but no significant symptoms at other times of the year. She has no history of a psychotic or anxiety disorder. She does not smoke or drink alcohol. Her current stressors include relationship problems, and she would like to avoid sexual side effects. She denies using illicit drugs. Of the following, which is the most appropriate management for this patient?

TY is a 19-year-old male brought into the ER with the following presentation: unconscious, miosis, BP 90/52, HR 48, RR 8, temperature 95oF.  Which of the following substances is TY most likely acutely intoxicated with?

TR is a 27-year-old Veteran who recently returned from Afghanistan after 3 tours of duty. His chief complaint is persisting flashbacks and nightmares 4-5 days/week. He does admit to some depressive symptoms and irritability but he is mostly concerned with the flashbacks and nightmares as he is not able to get a good night’s rest. He is unwilling to start more than one medication.Which of the following medications would be the most appropriate for TR?

Which of the following is a concern if buprenorphine is started to soon after a patient’s last opioid use?

A 16-year-old boy with a history of attention-deficit/hyperactivity disorder and epilepsy has received trials of multiple stimulants, but none have adequately controlled his symptoms. His parents therefore would like to switch him to the nonstimulant medication atomoxetine, given its more favorable risk–benefit profile. Which of the following statements correctly describes a U.S. Food and Drug Administration (FDA) bolded warning regarding atomoxetine?

Which of the following is an effective treatment option for dissociative identity disorder (DID)?

What neurotransmitter is primarily synthesized in the Locus Ceruleus and serves as a key player in mediating the sympathetic nervous system, commonly associated with the “Fight or Flight” response?

Which of the following is true regarding sodium oxybate (GHB)?